XELJANZ Drug Patent Profile

Which patents cover Xeljanz, and when can generic versions of Xeljanz launch?

Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has seventy-five patent family members in fifty-two countries.

The generic ingredient in XELJANZ is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeljanz

A generic version of XELJANZ was approved as tofacitinib citrate by AJANTA PHARMA LTD on June 1^st, 2021.

Summary for XELJANZ

International Patents:	75
US Patents:	1
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	31
Patent Applications:	811
Drug Prices:	Drug price information for XELJANZ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELJANZ
What excipients (inactive ingredients) are in XELJANZ?	XELJANZ excipients list
DailyMed Link:	XELJANZ at DailyMed

See drug prices for XELJANZ

Recent Clinical Trials for XELJANZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Brest	PHASE3
Eli Lilly and Company	PHASE3
Takeda	Phase 4

See all XELJANZ clinical trials

Pharmacology for XELJANZ

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for XELJANZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ	Oral Solution	tofacitinib citrate	1 mg/mL	213082	1	2021-11-12
XELJANZ	Tablets	tofacitinib citrate	10 mg	203214	1	2019-07-24
XELJANZ	Tablets	tofacitinib citrate	5 mg	203214	3	2016-11-07

US Patents and Regulatory Information for XELJANZ

XELJANZ is protected by one US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020	AA	RX	Yes	Yes	RE41783*PED				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	AB	RX	Yes	Yes	RE41783*PED				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	AB	RX	Yes	No	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	AB	RX	Yes	Yes	10,639,309*PED				Y

Expired US Patents for XELJANZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	7,301,023
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	7,091,208
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020	6,956,041
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	7,301,023

International Patents for XELJANZ

See the table below for patents covering XELJANZ around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1905	Pyrrolo[2,3-d] Pyrimidine Compounds.
Argentina	026534	COMPUESTOS DE PIRROLO[2,3-D]PIRIMIDINA, COMPOSICION FARMACEUTICA QUE LOS CONTIENE, SU USO COMO MEDICAMENTO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO Y COMBINACION DE LOS MISMOS CON AGENTAS MODULADORES DEL SISTEMA INMUNE O ANTIINFLAMATORIO
Austria	257157
Austria	380031

Supplementary Protection Certificates for XELJANZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1235830	C01235830/01	Switzerland		PRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013
1666481	300887	Netherlands		PRODUCT NAME: TOFACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TOFACITINIBCITRAAT; REGISTRATION NO/DATE: EU/1/17/1178 20170324
1666481	CA 2017 00035	Denmark		PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
1666481	PA2017025	Lithuania		PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322

Last updated: July 22, 2026

XELJANZ (tofacitinib) Market Dynamics and Financial Trajectory: Sales Drivers, Competition, and Patent/Generic Timeline

Executive summary: Xeljanz (tofacitinib) revenue moved with (1) rheumatoid arthritis (RA) uptake and label expansion, (2) the timing and severity of safety communications that pressured share, and (3) competitive switching after methotrexate-based regimens, biologics, and later JAK inhibitor rivals (notably Rinvoq). Patent and exclusivity do not fully eliminate generic risk in the U.S. because key composition-of-matter and formulation exclusivity have largely run out for small molecules, shifting value from monopoly period to litigation leverage and market access. Xeljanz remains a meaningful franchise but has faced sustained share pressure from newer JAK inhibitors with more favorable benefit framing in payer and prescriber workflows.

---

How has XELJANZ revenue evolved by indication (RA, PsA, AS, UC) and what drives net sales?

Direct answer: Xeljanz revenue has historically tracked a mix of (a) expansion in RA to broader JAK-inhibitor eligible populations, (b) step-up in utilization when psoriatic arthritis (PsA), ankylosing spondylitis (AS), and ulcerative colitis (UC) labels are adopted in routine care, and (c) payer sensitivity to safety communications and class competition.

Key commercial indication mechanics

RA (core historical anchor):

• Xeljanz reached mainstream uptake as an oral option for patients inadequately controlled on methotrexate.
• Growth typically depended on neurologic “tolerability and convenience” perception (oral dosing, no infusions) versus biologic treatment burden.

PsA and AS (second tier growth):

• Uptake is usually slower than RA due to smaller eligible populations and tighter sequencing against established biologics.
• Share gains tend to be strongest when payers approve after csDMARD or TNF failure.

UC (high-potential but execution sensitive):

• UC tends to be more sensitive to payer prior authorization criteria and safety messaging.
• Competitive dynamics are intense because multiple oral and biologic options exist, and conversion rates depend on induction-to-maintenance adherence.

What changed the financial trajectory

Safety communications and label tightening in the JAK class:

• The class has faced increased scrutiny tied to major adverse cardiovascular events, malignancy, and thrombosis risk signals. Xeljanz’s prescribing and payer adoption patterns changed as label warnings and boxed warnings tightened.
• After safety communications, new starts slowed while some ongoing patients remained on therapy, creating a “lower growth, flatter-to-down net sales” profile.

Switching to newer JAK inhibitors:

• Over time, prescribers and payers shifted toward newer JAK inhibitor profiles and brand positioning, notably AbbVie’s Rinvoq (upadacitinib) as the dominant competitor.
• This channel competition typically compresses pricing power and reduces patient acquisition momentum.

Plan design and net-to-gross:

• JAK inhibitors face aggressive contracting in the U.S. with manufacturer rebates tied to formulary tiers and utilization thresholds.
• Net sales trajectory often depends on rebate intensity more than headline list price.

---

What market share and class competition dynamics affect XELJANZ versus Rinvoq, Olumiant, and other RA/IBD options?

Direct answer: Xeljanz competes in a crowded JAK inhibitor field and against biologic and oral csDMARD strategies. Financial performance is most sensitive to market share losses driven by formulary placement, prior authorization rules, and safety framing relative to the class.

Where Xeljanz sits in payer and provider choice

• Oral convenience keeps it in consideration for patients preferring non-injectables.
• Class risk perception affects new starts. When payers tighten criteria or clinicians delay switching, Xeljanz growth slows.
• Access barriers (step edits, TB screening, lab monitoring requirements, non-preferred tier placement) influence utilization.

Competitive pressures by therapeutic area

RA:

• Primary rivals: Rinvoq (upadacitinib) and Olumiant (baricitinib), plus TNF inhibitors and abatacept.
• Commercial impact: newer JAK entry and biologic biosimilar erosion (in infliximab, adalimumab, etanercept classes) can force price concessions across the category.

PsA and AS:

• Rivals: other JAK inhibitors, TNF inhibitors, IL-17/IL-23 axis therapies in relevant subsets.
• Commercial impact: patients often cycle after biologic failure, creating competitive churn.

UC:

• Rivals: Xeljanz, Rinvoq, Entyvio-class agents, Stelara-class and IL-23 agents, and other small molecules depending on regional availability.
• Commercial impact: induction-to-maintenance retention determines lifetime value, and safety communications can shift sequencing.

---

When does XELJANZ lose exclusivity and what generic or biosimilar risks exist?

Direct answer: For tofacitinib, U.S. small-molecule exclusivity has largely matured and generic entry risk is governed more by patent expiration, Orange Book listings coverage, and litigation posture than by primary regulatory exclusivity alone. In practice, Xeljanz faces “late-cycle” value erosion through generic approvals and/or authorized generics if patent coverage is not blocking.

How to evaluate generic entry risk for Xeljanz

• Orange Book patent coverage determines whether a future ANDA is blocked by unexpired patents or triggers litigation via Paragraph IV.
• Patent stratification matters:
  • composition-of-matter
  • method-of-use (indication-specific)
  • formulation and process patents (including extended release, dosing, polymorphs if claimed)
• Settlement agreements can convert litigation into a date-certain launch window.

U.S. generic entry pathways

• ANDA with Paragraph IV: challenger asserts non-infringement and/or invalidity of listed patents.
• Hatch-Waxman litigation: triggers 30-month stay if appropriate.
• Possible resolution: settlement with an agreed entry date and sometimes an agreed “carve-out” tied to strength, dosage form, or indication.

---

What is the Orange Book status of tofacitinib (XELJANZ) and which patents are most likely to block ANDAs?

Direct answer: Orange Book status for tofacitinib is typically characterized by multiple listed patents spanning composition-of-matter and secondary patents. The most likely ANDA blockers are the last surviving patents that cover the commercial dosage form(s) and marketed strengths.

How to map patent layers to ANDA exposure

Composition-of-matter patents

• If any remain unexpired for a specific salt/form or polymorph family, they block direct generic copying.

Method-of-use patents

• Some method claims can block generic entry for specific indications while not necessarily preventing generic approval for other indications.
• This affects commercial timing because labeling carve-outs reduce total market access at launch.

Formulation and process

• Formulation patents can block generic if the generic can’t use a materially different formulation without triggering infringement.
• Process patents tend to be harder to police unless manufacturing steps are tied to unique intermediates or conditions.

Featured snippet: What blockers matter most

• The blockers that matter most for launch timing are the last unexpired patents covering the exact dosage strengths and FDA-approved labeling (or those that are enforced via method-of-use claims).

---

What patent litigation affects XELJANZ and how have settlement terms shaped launch timelines?

Direct answer: Xeljanz’s value exposure has been shaped by Hatch-Waxman litigation around listed Orange Book patents for tofacitinib strengths and indications. Settlement agreements in these cases typically trade uncertainty for a date-certain generic launch and sometimes specify labeling restrictions.

Litigation mechanics that matter for financial forecasting

• 30-month stay can delay launch if a Paragraph IV suit is filed.
• Court rulings on infringement/invalidity decide whether the generic can enter earlier than expected.
• Settlements can accelerate or delay launch relative to the calendar based on patent strength perceptions.

Commercial implication

• When settlement dates align with the end of formulary contracting cycles, the impact shows up as abrupt margin compression for the originator rather than a gradual decline.

---

What formulations are protected for XELJANZ and do they constrain generic competition?

Direct answer: Xeljanz protections commonly include formulation-level patents tied to specific dosage forms and manufacturing methods. Generic feasibility depends on whether challengers can produce equivalent products without infringing those claims.

Where formulation protection shows up in real-world access

• Strength-specific coverage matters: if only certain strengths are protected, the generic can launch partial lines.
• Indication carve-outs interact with formulation constraints:
  • even if a generic can market one strength, method-of-use restrictions can limit reimbursement or prior authorization coverage.
• Patient switching inertia: originators often retain patients on existing prescriptions during the transition period.

---

How does XELJANZ compare with Rinvoq on commercial momentum, prescriber adoption, and payer preference?

Direct answer: Rinvoq has generally benefited from strong prescriber and payer preference dynamics relative to Xeljanz through label positioning and competitive positioning within the JAK class. That dynamic translates into net sales share pressure for Xeljanz, especially in RA where acquisition is most active.

Practical drivers of comparative adoption

• Benefit-framing under label warnings: prescriber comfort and payer tiering often depend on which agent is perceived as best aligned to the patient risk profile.
• Formulary logic: pharmacy benefit managers often prefer one “preferred JAK” per line of therapy.
• Rebates and contracting: originators and competitors bid for preferred status, affecting net sales even when volume appears stable.

---

What FDA regulatory milestones and label changes have impacted XELJANZ uptake and revenue?

Direct answer: Safety-driven label changes and prescribing restrictions in the JAK class have been key inflection points impacting new patient starts, payer coverage decisions, and physician behavior.

Regulatory events that typically move revenue

• Label expansion (new indications) creates incremental demand and can lift adoption.
• Safety warnings and boxed warning changes reduce initiation rates, especially in patients without strong treatment alternatives.
• Post-marketing requirements and evolving guideline alignment can shift the eligible population for JAK inhibitors.

---

What are the main manufacturing and supply chain/IP barriers to generic entry for tofacitinib?

Direct answer: For small molecules like tofacitinib, manufacturing barriers are usually less decisive than patent and regulatory labeling barriers. However, formulation-level and process-level patents can still constrain product equivalency strategies.

Key constraints

• Equivalent dissolution/particle properties can implicate formulation claims if patents cover critical parameters.
• Process patents tied to specific synthetic routes can create infringement arguments even for chemically equivalent active ingredients.
• Quality-system compliance affects launch readiness and timing relative to litigation outcomes.

---

How much revenue risk does XELJANZ face from generic launch scenarios (strength, label, and timing)?

Direct answer: Xeljanz’s revenue risk is best understood as a function of (1) the number of unexpired patents for each strength and indication, (2) expected 30-month stay or settlement date, and (3) the probability of launch with full labeling versus carve-outs.

Scenario framework (U.S.)

• Scenario A: Full launch with broad labeling
  • Largest margin shock due to immediate competition across commercial demand.
• Scenario B: Strength-limited launch
  • Slower revenue erosion; prescribers may remain on non-launched strengths longer.
• Scenario C: Indication-limited launch
  • Reduced addressable market at launch; originator retains core indications not covered by generic labeling.

---

Key Takeaways

• Xeljanz’s financial trajectory is driven by RA and IBD adoption plus ongoing JAK-class competition, with safety communications shaping new-start velocity and payer access.
• Generic and ANDA risk is governed by Orange Book patent layers covering composition, method-of-use, and formulation. Launch timing depends on which patents remain enforceable and how Paragraph IV litigation or settlements resolve.
• Competitive pressure from Rinvoq and broader biologic biosimilar erosion has compressed growth expectations and increased rebate intensity.
• The most material revenue risk comes from date-certain generic entry aligned with full labeling and preferred formulary placement by competitors.

---

FAQs

1. What FDA labeling restrictions most affect Xeljanz new patient starts in the JAK class?
2. How do Paragraph IV filings and Hatch-Waxman stays typically translate into calendar-based generic launch delays for tofacitinib?
3. Can an ANDA launch tofacitinib with carve-outs that limit reimbursement or formulary coverage for specific indications?
4. Which patent categories for tofacitinib usually provide the longest enforcement tail: composition, method-of-use, or formulation?
5. How does biosimilar erosion of biologic competitors indirectly impact Xeljanz pricing and net sales?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration. FDA Drug Safety Communications and label updates for JAK inhibitors (tofacitinib and class updates).
3. FDA. Prescribing Information for XELJANZ (tofacitinib) and label history.
4. Hatch-Waxman Amendments (21 U.S.C. § 355(j)) and Paragraph IV litigation framework (30-month stay provisions).

DrugChatter Q&A for XELJANZ

When will generic xeljanz be available in the iss?
Why did bc delist xeljanz?
Xeljanz generic alternative?
Xeljanz indications patent?
Is there a generic for xeljanz xr?